人肝星状细胞多模态分析识别代谢功能障碍相关脂肪性肝病新治疗靶点
该研究对18例正常、MASL和MASH人肝组织进行单核RNA测序和单核ATAC测序,比较肝星状细胞转录组和染色质可及性,发现MASH富集的活化肝星状细胞亚群是细胞外基质蛋白主要来源,并鉴定出GAS7、SPON1、SERPINE1等核心上调基因,通过二维细胞、三维球体和基因敲除小鼠验证了SERPINE1(PAI-1)的致病作用及遗传或药理抑制可抑制肝纤维化。
要点
- MASH富集的活化肝星状细胞亚群是细胞外基质蛋白的主要来源。
- 鉴定出GAS7、SPON1、SERPINE1、LTBP2、KLF9、EFEMP1等核心上调且染色质更开放基因。
- 遗传或药理抑制SERPINE1(PAI-1)可抑制肝纤维化,靶向RUNX1/2-SERPINE1轴或是治疗新策略。
核心结论
- 本研究识别了MASH中促纤维化肝星状细胞活化的新基因靶点和调控机制,并证明遗传或药理抑制选定基因可抑制肝纤维化。
- 活化肝星状细胞来源的PAI-1(SERPINE1基因产物)在MASH肝纤维化发展中起致病作用,靶向RUNX1/2-SERPINE1轴可能是治疗肝纤维化的新策略。
研究设计与样本
- 研究对18例人肝组织进行单核RNA测序和单核ATAC测序,比较正常、MASL和MASH肝星状细胞的转录组和染色质可及性。
- 鉴定出的高优先级靶点在二维人肝星状细胞培养、三维人肝球体和肝星状细胞特异性基因敲除小鼠中进行验证。
主要发现
- MASH富集的活化肝星状细胞亚群是细胞外基质蛋白的主要来源。
- 鉴定出一组同时上调且染色质更开放的核心基因(GAS7、SPON1、SERPINE1、LTBP2、KLF9、EFEMP1),驱动肝星状细胞活化。
- 这些基因的表达通过谱系特异性(JUNB/AP1)、簇特异性(RUNX1/2)和信号特异性(FOXA1/2)转录因子之间的交互调控。
- 在三维人MASH肝球体中采用dsiRNA敲低肝星状细胞特异性基因或药理抑制PAI-1,以及在肝星状细胞特异性Serpine1敲除小鼠中,证实了SERPINE1(PAI-1)等选定靶点的病理相关性。
- 本研究识别了既往研究未检测到的额外亚群,并首次描述了活化肝星状细胞来源的PAI-1在MASH肝纤维化发展中的致病作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Metabolic dysfunction-associated steatotic liver disease ranges from metabolic dysfunction-associated steatotic liver (MASL) to metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis. Transdifferentiation of hepatic stellate cells (HSCs) into fibrogenic myofibroblasts plays a critical role in the pathogenesis of MASH liver fibrosis. We compared transcriptome and chromatin accessibility of human HSCs from NORMAL, MASL, and MASH livers at single-cell resolution. We aimed to identify genes that are upregulated in activated HSCs and to determine which of these genes are key in the pathogenesis of MASH fibrosis. METHODS: Eighteen human livers were profiled using single-nucleus (sn)RNA-seq and snATAC-seq. High priority targets were identified, then tested in 2D human HSC cultures, 3D human liver spheroids, and HSC-specific gene knockout mice. RESULTS: MASH-enriched activated HSC subclusters are the major source of extracellular matrix proteins. We identified a set of concurrently upregulated and more accessible core genes (GAS7, SPON1, SERPINE1, LTBP2, KLF9, EFEMP1) that drive activation of HSCs. Expression of these genes was regulated via crosstalk between lineage-specific (JUNB/AP1), cluster-specific (RUNX1/2) and signal-specific (FOXA1/2) transcription factors. The pathological relevance of the selected targets, such as SERPINE1 (PAI-1), was demonstrated using dsiRNA-based HSC-specific gene knockdown or pharmacological inhibition of PAI-1 in 3D human MASH liver spheroids, and HSC-specific Serpine1 knockout mice. CONCLUSION: This study identified novel gene targets and regulatory mechanisms underlying activation of fibrogenic HSCs in MASH, and demonstrated that genetic or pharmacological inhibition of select genes suppressed liver fibrosis. IMPACT AND IMPLICATIONS: Herein, we present the results of a multi-modal sequencing analysis of human hepatic stellate cells (HSCs) from NORMAL, MASL (metabolic dysfunction-associated steatotic liver), and metabolic dysfunction-associated steatohepatitis (MASH) livers. We identified additional subclusters that were not detected by previous studies and characterized the mechanism by which HSCs are activated in MASH livers, including the transcriptional machinery that induces the transdifferentiation of HSCs into myofibroblasts. For the first time, we described the pathogenic role of activated HSC-derived PAI-1 (a product of the SERPINE1 gene) in the development of MASH liver fibrosis. Targeting the RUNX1/2-SERPINE1 axis could be a novel strategy for the treatment of liver fibrosis in patients.
引用
- Kim HY, Rosenthal SB, Liu X, et al. Multi-modal analysis of human hepatic stellate cells identifies novel therapeutic targets for metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2024. PMID: 39522884. doi:10.1016/j.jhep.2024.10.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。